Literature DB >> 15161083

Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum-derived rhoptry-associated protein 1 peptides.

Hernando Curtidor1, Marisol Ocampo, Diana Tovar, Ramses López, Javier García, Jhon Valbuena, Ricardo Vera, Jorge Suárez, Luis E Rodríguez, Alvaro Puentes, Fanny Guzmán, Elizabeth Torres, Manuel E Patarroyo.   

Abstract

Rhoptry-associated protein 1 (RAP1) is a merozoite antigen within Plasmodium falciparum rhoptries as yet having no specific function described for it. Synthetic peptides spanning the RAP1 sequence were tested in erythrocyte binding assays to identify possible RAP1 functional regions. Five high activity binding peptides (HABPs) were identified; 26201, 26202, 26203 and 26204 spanned residues 461C-K540 within RAP1 Cys region, whilst 26188 (201T-Y220) was located in p67 amino terminal. The results showed that peptide binding was saturable, some HABPs inhibited in vitro merozoite invasion and specifically bound to a 72 kDa protein in red blood cell membrane. HABP possible function in merozoite invasion of erythrocytes is also discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161083     DOI: 10.1016/j.vaccine.2003.07.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Evidence for negative selection on the gene encoding rhoptry-associated protein 1 (RAP-1) in Plasmodium spp.

Authors:  M Andreína Pacheco; Elizabeth M Ryan; Amanda C Poe; Leonardo Basco; Venkatachalam Udhayakumar; Williams E Collins; Ananias A Escalante
Journal:  Infect Genet Evol       Date:  2010-04-02       Impact factor: 3.342

2.  Erythrocyte Binding Activity Displayed by a Selective Group of Plasmodium vivax Tryptophan Rich Antigens Is Inhibited by Patients' Antibodies.

Authors:  Rupesh Kumar Tyagi; Yagya Dutta Sharma
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

Review 3.  Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.

Authors:  M E Patarroyo; G Cifuentes; A Bermúdez; M A Patarroyo
Journal:  J Cell Mol Med       Date:  2008-10       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.